Teneligliptin real-world efficacy assessment of type 2 diabetes mellitus patients in India (TREAT-INDIA study)

por Ghosh S, Trivedi S, Sanyal D, Modi KD, Kharb S
Publicado 2016

Tolerability and efficacy of glycemic control with saxagliptin in older patients (aged ≥ 65 years) with inadequately controlled type 2 diabetes mellitus

por Karyekar CS, Ravichandran S, Allen E, Fleming D, Frederich R
Publicado 2013

Saxagliptin for type 2 diabetes

por Chacra
Publicado 2010

Experience with sitagliptin (the first DPP-4 inhibitor) application to the treatment of type 2 diabetes mellitus in the Russian Federation:Results of the DIA-DA observation program

por Marina Vladimirovna Shestakova
Publicado 2010

Russian Association of Endocrinologists reports commencement of Trajenta clinical use

por Editorial team Diabetes Mellitus
Publicado 2012

Teneligliptin in management of type 2 diabetes mellitus

por Sharma SK, Panneerselvam A, Singh KP, Parmar G, Gadge P, Swami OC
Publicado 2016

Add-On Therapy with DPP-4 Inhibitors May Improve Renal Function Decline in α-Glucosidase Inhibitor and Metformin Users: A Retrospective Observational Study

por Osonoi T, Saito M, Koda N, Douguchi S, Nakano T, Ofuchi K, Katoh M
Publicado 2020

Influence of type-4 dipeptidyl peptidase inhibition on endothelium-dependent relaxation of aortae from a db/db mouse model of type 2 diabetes: a comparison with the effect of glime...

por Woodman OL, Ortega JM, Hart JL, Klein T, Potocnik S
Publicado 2019

Effect of Anagliptin versus Sitagliptin on Inflammatory Markers: Sub-Analysis from the REASON Trial

por Teragawa H, Morimoto T, Fujii Y, Ueda T, Sakuma M, Shimabukuro M, Arasaki O, Node K, Nomiyama T, Ueda S
Publicado 2020

First Russian DPP-4 inhibitor Gosogliptin comparing to Vildagliptin in type 2 diabetes mellitus patients

por Karina Oganesovna Galstyan, Liudmila Viktorovna Nedosugova, Nina Alexandrovna Petunina, Julia Alexandrovna Trakhtenberg, Natalia Vadimovna Vostokova, Oksana Vladimirovna Karavaeva, Tatiana Evgenievna Chasovskaya
Publicado 2016

Linagliptin use in older individuals with type 2 diabetes

por Pratley RE
Publicado 2014

Expert committee on novel DPP-4 inhibitor TRADJENTA (linagliptin) in treatment of type 2 diabetes mellitus

por Editorial team Diabetes Mellitus
Publicado 2012

Rannyaya kombinirovannaya terapiya pri sakharnom diabete 2 tipa

por Alexander Sergeevich Ametov, Ekaterina Vladimirovna Karpova
Publicado 2011

Clinical implementetion of vildagliptin: data from recent studies comparing incretin-based medications

por Elena Valer'evna Biryukova
Publicado 2014

Efficacious and safe management of type 2 diabetes mellitus using DPP-4 inhibitors

por Alexander Sergeevich Ametov, Ekaterina Vladimirovna Karpova
Publicado 2010

Initial investigation of efficacy and safety of a new dipeptidyl peptidase-4 inhibitor, gosogliptin, for type 2 diabetes in Russia

por Lyudmila Viktorovna Nedosugova, Nina Alexandrovna Petunina, Karina Oganesovna Galstyan
Publicado 2014

Comparative risk of musculoskeletal adverse reactions among new users of dipeptidyl peptidase-4 inhibitors: A retrospective cohort study

por Taehwan Park, Maureen Bresnahan, Scott K. Griggs, Jiajing Chen, Alex H. Cho, Yolene Gousse, Mark Feinglos
Publicado 2021

Heart failure in diabetes: effects of anti-hyperglycemic drug therapy

por Gagik R. Galstyan, Mikhail Y. Gilyarov
Publicado 2016

Effectiveness prediction of Evogliptin treatment in type 2 diabetes mellitus in russian-korean population

por Anna A. Mosikian, Alina Y. Babenko, Yulia A. Sevastyanova, Roman V. Drai, Evgenij V. Shlyakhto
Publicado 2018

Expert committee on introduction of incretin-based therapy in Russia: advance and failure

por Editorial team Diabetes Mellitus
Publicado 2012